Investment Summary

HBM Partners AG Invests In Genalyte

On January 11, 2021, private equity firm HBM Partners AG invested in life science company Genalyte

Investment Highlights
  • This is HBM Partners AG’s 44th transaction in the Life Science sector.
  • This is HBM Partners AG’s 34th transaction in the United States.
  • This is HBM Partners AG’s 16th transaction in California.

Investment Summary
Date 2021-01-11
Target Genalyte
Sector Life Science
Investor(s) HBM Partners AG
Deal Type Venture

Target

Genalyte

San Diego, California, United States
Genalyte is a healthcare diagnostics and analytics company that improves patient outcomes and lowers cost with real-time results for physicians and patients. Genalyte was founded in 2007 and is based in San Diego, California.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

HBM Partners AG

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2001
PE ASSETS 3.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.

DEAL STATS #
Overall 51 of 66
Sector (Life Science) 44 of 57
Type (Venture) 41 of 53
State (California) 16 of 18
Country (United States) 34 of 44
Year (2021) 3 of 15
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-11 Valo Health

Lex­ing­ton, Massachusetts, United States

Valo Health is a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence driven computation. Valo Health was founded in 2019 and is based in Lex­ing­ton, Massachusetts.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-13 IO Biotech

Copenhagen, Denmark

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. IO Biotech's pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech was founded in 2014 and is based in Copenhagen, Denmark.

Buy -
Mergr

Product

Company

Legal